Average Insider

Where insiders trade, we follow

$ZYME
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
Healthcare
Sector
Biotechnology
Industry
Kenneth H. Galbraith
CEO
299
Employees
$26.06
Current Price
$1.75B
Market Cap
52W Low$21.52
Current$26.0643.4% above low, 56.6% below high
52W High$31.97

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00--All Sells
Sells24$1,417,496.4455,033
2 weeksBuys00--All Sells
Sells24$1,417,496.4455,033
1 monthBuys00--All Sells
Sells24$1,417,496.4455,033
2 monthsBuys00--All Sells
Sells35$1,775,053.6468,865
3 monthsBuys00--All Sells
Sells35$1,775,053.6468,865
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Nov 18, 2026
Platshon Scott
EVP, Chief Business Officer
Sale15,292$24.95$381,535.40View Details
Nov 13, 2026
Moore Paul Andrew
Chief Scientific Officer
Sale7,374$26.09$192,387.66View Details
Nov 13, 2026
Moore Paul Andrew
Chief Scientific Officer
Sale25,000$26.04$651,000.00View Details
Nov 13, 2026
Moore Paul Andrew
Chief Scientific Officer
Sale7,367$26.14$192,573.38View Details
Oct 9, 2026
Schayowitz Adam
EVP, Head of R&D
Sale13,832$25.85$357,557.20View Details
10 more transactions available โ€” create a free account to see 12 months of history

Upcoming Earnings

Scheduled earnings reports
No upcoming earnings scheduled

Past Earnings

Historical earnings results
Nov 9, 2026
EPS
Estimated$2.27
ActualN/A
Revenue
Estimated$227.40M
ActualN/A
Nov 5, 2026
EPS
Estimated$2.29
ActualN/A
Revenue
Estimated$227.39M
ActualN/A
2 more earnings records available โ€” create a free account to see 12 months of history

Related Activity

Cross-company insider connections and cluster buy signals
Version: v26.11.1